SCHEMBL4206804

SCHEMBL4206804

CC(C)C(N)CO[C@H]1CCCCO1

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4206806 1.00 MEN1 (0.33) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL28517849 0.86 MEN1 (0.35) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4496192 0.82 MEN1 (0.36) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL20236951 0.80 MEN1 (0.35) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL19361665 0.80 MEN1 (0.35) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL21594584 0.80 MEN1 (0.33) MEN1KMT2A
SCHEMBL1990007 0.79 MEN1 (0.33) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL21594589 0.79 NOS2 (0.30)
SCHEMBL6994576 0.79 MEN1 (0.40) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL6994573 0.79 MEN1 (0.40) MEN1KMT2AKDM4CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2018-09-20 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 EP disclosed
EP-1992607-B1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2014-12-31 EP disclosed
US-20130345462-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2013-12-26 US disclosed
US-20130310595-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2013-11-21 US disclosed
US-8420821-B2 Process for production of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-04-16 US disclosed
US-8383819-B2 Method for producing 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-02-26 US disclosed
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-12-24 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345462-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 MEN1 3040/4885KMT2A 975/4885KDM4C 332/4885
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 MEN1 2469/4885KMT2A 647/4885KDM4C 598/4885
US-20130310595-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 MEN1 2469/4885KMT2A 647/4885KDM4C 598/4885
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 MEN1 2469/4885KMT2A 647/4885KDM4C 598/4885
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 MEN1 3040/4885KMT2A 975/4885KDM4C 332/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 MEN1 2469/4885KMT2A 647/4885KDM4C 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.